KR20080028763A - 미세소관 형성 저해제로서 유용한 벤조페논 유도체 - Google Patents
미세소관 형성 저해제로서 유용한 벤조페논 유도체 Download PDFInfo
- Publication number
- KR20080028763A KR20080028763A KR1020070083856A KR20070083856A KR20080028763A KR 20080028763 A KR20080028763 A KR 20080028763A KR 1020070083856 A KR1020070083856 A KR 1020070083856A KR 20070083856 A KR20070083856 A KR 20070083856A KR 20080028763 A KR20080028763 A KR 20080028763A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- methanone
- phenyl
- trimethoxyphenyl
- furan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
화합물 | HL60 생장 억제 (μM) | 튜불린 중합체 형성 억제 (μM) |
200 | 0.13 | |
203 | 0.035 | 3.2 |
206 | 0.145 | |
209 | 0.54 | |
213 | 0.137 | 5.9 |
224 | 0.11 | 2.5 |
225 | 0.058 | 8.07 |
226 | 0.37 | 1.07 |
231 | 0.12 | 3.03 |
235 | 0.28 | 4.47 |
237 | 0.27 | 6.03 |
238 | 0.34 | 6.74 |
241 | 0.09 | 4.48 |
249 | 0.12 | 6.68 |
264 | 0.48 | 8.23 |
265 | 0.39 | 7.43 |
269 | 1.69 | 7.92 |
272 | 1.34 | >10 |
277 | 0.11 | |
278 | 0.03 | 3.91 |
279 | 0.13 | |
282 | 0.15 | |
283 | 0.048 | |
286 | 0.07 | 1.34 |
289 | 0.007 | 2.31 |
293 | 0.017 | |
296 | 1.23 | 1.33 |
294 | 0.10 | |
297 | 0.035 | 3.61 |
298 | 0.16 | 2.60 |
300 | 0.17 | |
301 | 0.08 | |
308 | 0.19 | 2.51 |
316 | 0.14 | 1.39 |
322 | 0.17 | 2.37 |
323 | 0.17 | 2.01 |
327 | 0.09 | |
335 | 0.22 | 5.57 |
337 | 0.19 | |
341 | 0.11 | 4.33 |
346 | 0.10 | 3.37 |
347 | 0.03 | 3.22 |
348 | 0.10 | 3.95 |
354 | 0.11 | |
359 | 0.10 | 7.71 |
363 | 0.11 | 2.47 |
화합물 | HL60 생장 억제 (μM) | 튜불린 중합체 형성 억제 (μM) |
365 | 0.07 | 1.84 |
372 | 0.11 | 8.57 |
374 | 0.1 | 2.15 |
375 | 0.04 | 1.70 |
379 | 0.11 | 5.41 |
380 | 0.11 | 3.11 |
391 | 0.12 | 3.45 |
399 | 0.11 | |
401 | 0.03 | 2.66 |
409 | 0.03 | 3.31 |
410 | 0.10 | |
442 | 0.033 | 4.51 |
443 | 0.08 | |
446 | 0.17 | 5.53 |
455 | 3.10 | |
457 | 11.58 | |
458 | 3.18 | |
462 | 0.033 | 4.64 |
464 | 0.09 | 8.70 |
476 | 0.025 | |
479 | 0.025 | |
484 | 4.24 | |
486 | 0.16 | |
494 | 0.12 | |
506 | 0.16 | |
511 | 0.10 |
화합물 | HL60 생장 억제 (μM) |
519 | 25 |
525 | 0.09 |
531 | 0.33 |
534 | 0.06 |
538 | 0.28 |
547 | 0.03 |
550 | 0.02 |
554 | 0.09 |
560 | 0.09 |
561 | 0.32 |
562 | 0.08 |
563 | 0.25 |
564 | 0.09 |
568 | 0.36 |
570 | 0.12 |
571 | 0.11 |
581 | 0.04 |
583 | 0.01 |
587 | 0.04 |
588 | 0.12 |
590 | 0.01 |
591 | 0.20 |
594 | 0.12 |
595 | 0.12 |
596 | 0.23 |
597 | 0.22 |
598 | 0.39 |
599 | 0.14 |
601 | 0.09 |
602 | 0.17 |
Claims (19)
- 하기 화학식 Ⅰ의 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.[화학식 I]상기 식에서, R1, R2, R3, R4 및 R5는 같거나 다를 수 있고, 서로 인접한 탄소와 연결되어 다이옥산 또는 다이옥솔레인 고리를 형성할 수 있으며, 각각 수소, 하이드록시, 하이드록시알킬, 플루오로, 브로모, 클로로, C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 포르밀, [1,3]다이옥산, 또는 하기 구조식 1로 표시되는 잔기로;[구조식 1]여기에서, q는 1 또는 2이고, R6 및 R7은 각각 수소 또는 C1 -3의 알킬이고;Z는 O, S, CH2, 또는 하기 구조식 2로 표시되는 잔기로,[구조식 2]여기에서, R8은 수소 또는 C1 -3의 알킬이며;X는 C 또는 N이며, X가 C일 때 Rb는 수소, C1 -3의 알콕시, C1 -6의 치환되거나 비치환된 알킬 또는 상기 구조식 1로 표시되는 잔기이고, X가 N일 때 Rb는 존재하지 않으며;Ra는 수소, 플루오로, -CONH2, -COOH, 나이트로, -O-R9(여기에서 R9는 수소, C1 -6의 치환되거나 비치환된 알킬, 페닐, -SO2-R10, -CO2R10, 여기에서 R10은 C1 -6의 치환되거나 비치환된 알킬 또는 치환되거나 비치환된 페닐), -CO-R10 또는 -COO-R10(여기에서 R10은 상기에서 정의한 바와 같다), 하기 구조식 3의 잔기이거나,[구조식 3]여기에서 R11 및 R12는 각각 독립적으로 수소, 포르밀, C1 -3의 알콕시, 피리딘, 피리미딘, C1 -6의 치환되거나 비치환된 알킬, 하이드록시알킬, -CO-R10, -COO-R10 또는 -SO2-R10으로, 이 때 R10은 상기에서 정의한 바와 같고,또는 O, S 및 N으로 이루어진 그룹으로부터 선택된 하나 이상의 헤테로원자를 임의로 포함하는 C5 또는 C6의 헤테로환(당해 환은 치환기가 없거나, 하나 이상의 C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 티올, 아미노, 나이트로, 티오메틸, 카르복시산, 메틸카르복실레이트, -CF3 또는 -NR13R14로 임의로 치환되며, 여기에서 R13, R14는 각각 독립적으로 C1 -6의 치환되거나 비치환된 알킬, 하이드록시알킬, -CO-R10, COO-R10, 또는 SO2-R10으로, R10은 상기에서 정의한 바와 같다)이고;Rc 및 Rd는 각각 독립적으로 수소이거나, 또는 O, S 및 N으로 이루어진 그룹으로부터 선택된 하나 이상의 헤테로원자를 임의로 포함하는 C5 또는 C6의 헤테로환(당해 환은 치환기가 없거나, 하나 이상의 C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시 또는 -NR13R14에 의해 임의로 치환되며, 여기에서 R13, R14는 상기에서 정의한 바와 같다), 또는 R15로 치환된 페닐(여기에서 R15는 수소, 하이드록시, 나이트로, C1-6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 플루오로, 나이트릴, -NR11R12, -COO-R10, 또는 -SO2-R10이며, 여기서 R10, R11, 및 R12는 상기에서 정의한 바와 같다)이고, 단, Rc 및 Rd는 동시에 수소일 수는 없고;Re는 수소 또는 할로겐이다.
- 제 1 항에 있어서, 하기 화학식 Ⅰ의 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.[화학식 I]상기 식에서, R1, R2, R3, R4 및 R5는 같거나 다를 수 있고, 각각 하이드록시, 하이드록시알킬, 플루오로, 브로모, C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 포르밀, 또는 하기 구조식 1로 표시되는 잔기로;[구조식 1]여기에서, q는 1 또는 2이고, R6 및 R7은 각각 수소 또는 C1 -3의 알킬이고;Z는 O, S, CH2, 또는 하기 구조식 2로 표시되는 잔기로,[구조식 2]여기에서, R8은 수소 또는 C1 -3의 알킬이며;X는 C 또는 N이며, X가 C일 때 Rb는 수소, C1 -3의 알콕시, C1 -6의 치환되거나 비치환된 알킬 또는 상기 구조식 1로 표시되는 잔기이고, X가 N일 때 Rb는 존재하지 않으며;Ra는 수소, 플루오로, -CONH2, -COOH, 나이트로, -O-R9(여기에서 R9는 수소, C1-6의 치환되거나 비치환된 알킬, -SO2-R10, -CO2R10, 여기에서 R10은 C1 -6의 치환되거나 비치환된 알킬 또는 치환되거나 비치환된 페닐), 하기 구조식 3의 잔기이거나,[구조식 3]여기에서 R11 및 R12는 각각 독립적으로 수소, 포르밀, C1 -3의 알콕시, 피리딘, 피리미딘, C1 -6의 치환되거나 비치환된 알킬, 하이드록시알킬, -CO-R10, -COO-R10 또는 -SO2-R10으로, 이 때 R10은 상기에서 정의한 바와 같고,또는 O, S 및 N으로 이루어진 그룹으로부터 선택된 하나 이상의 헤테로원자 를 임의로 포함하는 C5 또는 C6의 헤테로환(당해 환은 치환기가 없거나, 하나 이상의 C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 아미노, 나이트로, 티오메틸, 카르복시산, 메틸카르복실레이트, -CF3 또는 -NR13R14로 임의로 치환되며, 여기에서 R13, R14는 각각 독립적으로 C1 -6의 치환되거나 비치환된 알킬)이고;Rc 및 Rd는 각각 독립적으로 수소이거나, 또는 O, S 및 N으로 이루어진 그룹으로부터 선택된 하나 이상의 헤테로원자를 임의로 포함하는 C5 또는 C6의 헤테로환(당해 환은 치환기가 없거나, 하나 이상의 C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시 또는 -NR13R14에 의해 임의로 치환되며, 여기에서 R13, R14는 상기에서 정의한 바와 같다), 또는 R15로 치환된 페닐(여기에서 R15는 하이드록시, 나이트로, C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 플루오로, 나이트릴, -NR11R12, -COO-R10, 또는 -SO2-R10이며, 여기서 R10, R11, 및 R12는 상기에서 정의한 바와 같다)이고, 단, Rc 및 Rd는 동시에 수소일 수는 없고;Re는 수소이다.
- 제 1 항에 있어서, Ra가 하기 구조식으로 구성되는 군으로부터 선택되고[구조식 7]여기에서, R17은 메틸, 아미노, 나이트로, 티오메틸, 카르복시산, 메틸카르복실레이트 또는 CF3이고,Rc 또는 Rd는 각각 하기 구조식으로 구성되는 군으로부터 선택되는 잔기인 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.[구조식 8]여기에서, R15는 수소, 하이드록시, 나이트로, C1 -6의 치환되거나 비치환된 알킬, C1 -3의 알콕시, 플루오로, 나이트릴, -NR11R12, -COO-R10, 또는 -SO2-R10으로, 여기 에서 R10, R11 및 R12는 각각 상기에서 정의한 바와 같고;R16은 수소, 아미노, 아미노아실 또는 C1 -3의 알킬이다.
- 제 1 항에 있어서, Ra가 NH2인 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서, Ra가 C1 ∼3의 알콕시인 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서, R1, R2, R3, R4 및 R5가 각각 불소(fluorine)인 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서, R2, R3 및 R4가 각각 메톡시(methoxy)인 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서, 하기 화합물로부터 선택된 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물:화합물 200(2-메톡시-5-(피리딘-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 203(5-(푸란-2-일)-2-메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 206(5-(푸란-2-일)-2,3-다이메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 207(2,3-다이메톡시-5-(피리딘-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 211(4-메톡시-5'-나이트로바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 212(5'-아미노-4-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 213(4,4'-다이메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 214(4,6'-다이메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 216(4-에톡시-4'-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 218(6'-하이드록시-4-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 220(4-하이드록시-4'-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 223(4'-메톡시-4-나이트로바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 224(5-(푸란-2-일)-2-나이트로페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 225(2-아미노-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 226(4-아미노-4'-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 227(5-(푸란-2-일)-2-메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온 옥심;화합물 228(4-메톡시-3-(3,4,5-트라이메톡시벤조일)페닐)-1H-파이롤-1-카복실산 tert-부틸 에스테르;화합물 229(2-메톡시-5-(1H-파이롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 231N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 232(2-(벤질아미노)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 233(3-(1,3-다이옥산-2-일)-4,5-다이메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 2345-(5-(푸란-2-일)-2-메톡시벤조일)-2,3-다이메톡시벤즈알데하이드;화합물 235N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 2364-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐아미노)-4-옥소부탄산;화합물 2372-아미노-N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 238(2-(알릴아미노)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 239(R)-2-아미노-N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)-3-메틸 부탄아마이드;화합물 240(5-(푸란-2-일)-2-하이드록시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 241메탄설폰산 4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐;화합물 242(2-(2-(다이메틸아미노)에톡시)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 2432-(4-푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페녹시)아세트산 메틸 에스테르;화합물 2442-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페녹시)아세트산;화합물 245(5-(푸란-2-일)-2-메톡시페닐)(페닐)메탄온;화합물 246(5-(푸란-2-일)-2-메톡시페닐)(4-메톡시페닐)메탄온;화합물 247(3,4-다이메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 248벤조[d][1,3]다이옥솔-5-일(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 249(5-(푸란-2-일)-2-메톡시페닐)(3-(하이드록시메틸)-4,5-다이메톡시페닐)메탄온;화합물 253(4,5-다이메톡시-3-((메틸아미노)메틸)페닐)(5-푸란-2-일)-2-메톡시페닐)메탄온;화합물 255(5-(푸란-2-일)-2-메톡시페닐)(3-메톡시-4-(메톡시메톡시)페닐)메탄온;화합물 256(5-(푸란-2-일)-2-메톡시페닐)(4-하이드록시-3-메톡시페닐)메탄온;화합물 257(3-((다이메틸아미노)메틸)-4-하이드록시-5-메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 260(5-(푸란-2-일)-2-나이트로페닐)(3-메톡시-4-(메톡시메톡시페닐)메탄온;화합물 261(5-(푸란-2-일)-2-나이트로페닐)(4-하이드록시-3-메톡시페닐)메탄온;화합물 262(5-(푸란-2-일)-2,4-다이메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 263(3-((다이메틸아미노)메틸)-4,5-다이메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 264(5-(푸란-2-일)-2-메톡시페닐)(4-메톡시-3,5-다이메틸페닐)메탄온;화합물 265(5-(푸란-2-일)-2-메톡시페닐)(4-(메톡시메톡시)-3,5-다이메틸페닐)메탄온;화합물 266(5-(푸란-2-일)-2-메톡시페닐)(4-하이드록시-3,5-다이메틸페닐)메탄온;화합물 267(4-(2-(다이메틸아미노)에톡시)-3,5-다이메틸페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 268(4-(알릴옥시)-3-메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 269(3-알릴-4-하이드록시-5-메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 271N-(5-(1H-1,2,4-트리아졸-1-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 272(2-아미노-4-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 2732-(4-아세트아미도-3-(3,4,5-트라이메톡시벤조일)페닐)-1H-파이롤-1-카복실산 tert-부틸 에스테르;화합물 274N-(4-(1H-파이롤-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 275(3-알릴-4,5-다이메톡시페닐)((5-푸란-2-일)-2-메톡시페닐)메탄온;화합물 276(3-(2,3-다이하이드록시프로필)-4,5-다이메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 277N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 278(2-아미노-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 279N-(4-(티오펜-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 281N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)-N-메틸아세트아마이 드;화합물 282(5-(푸란-2-일)-2-(메틸아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 283(2-아미노-5-(티오펜-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 284(2-아미노-5-(옥사졸-5-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 285N-(2-(3-(하이드록시메틸)-4,5-다이메톡시벤조일)-4-(티아졸-2-일)페닐)아세트아마이드;화합물 286(2-아미노-5-(티아졸-2-일)페닐)(3-(하이드록시메틸)-4,5-다이메톡시페닐)메탄온;화합물 288N-(4-(피리딘-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 289(2-아미노-5-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 290(5-(1H-이미다졸-1-일)-2-나이트로페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 291(2-나이트로-5-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 293(2-아미노-5-(피리딘-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 294N-(4-(2-아미노티아졸-5-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 295N-(4-(2-메틸티아졸-5-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 296N-(4-(옥사졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 297(2-아미노-5-(2-아미노티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 298(2-아미노-5-(2-메틸티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 300N-(4-(티오펜-3-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 301(2-아미노-5-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 302N-(4-(6-메톡시피리딘-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 303(2-아미노-5-(6-메톡시피리딘-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 306(5-(푸란-2-일)-2-페녹시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 307N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)프로피온아마이드;화합물 308N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 3094-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐카복실산 메틸 에스테르;화합물 311N-(4-(1-메틸-1H-이미다졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 312(2-아미노-5-(1-메틸-1H-이미다졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 313N-(4-(1H-피라졸-5-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 3143-클로로-N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)프로판아마이드;화합물 3154-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐카복실산 이소부틸 에스테르;화합물 316N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)포름아마이드;화합물 317(5-(푸란-2-일)-2-(4-메틸피페라진-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 318(2-아미노-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온 옥심;화합물 3204-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐카복실산 헥실 에스테르;화합물 3214-메톡시-N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)벤젠설폰아마이드;화합물 322(5-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 323(5-(푸란-2-일)-2-(2-하이드록시에틸아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 324N-(4-(2-포름아마이드티아졸-4-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 326(2-아미노-5-(티아졸-2-일)페닐)(4-하이드록시-3,5-다이에톡시페닐)메탄온;화합물 327(2-플루오로-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 328(2-(메톡시아미노)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온 O-메틸 옥심;화합물 329(5-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(4-하이드록시-3,5-다이메톡시페닐)메탄온;화합물 330(2-(다이메톡시아미노)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 331(2-(다이플루오로메톡시)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 332(3-알릴-5-(푸란-2-일)-2-하이드록시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 333(3-알릴-2-(다이플루오로메톡시)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 3344-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐카복실산 2-메톡시메틸 에스테르;화합물 335N-(4-(피리딘-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 336(5-(푸란-2-일)-2-(1H-피라졸-1-닐)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 337(4,5'-다이아미노페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 338N-(5'-아미노-3-(3,4,5-트라이메톡시벤조일)바이페닐-4-일)아세트아마이드;화합물 339N-(4-(피리미딘-5-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 340(2-아미노-5-(피리미딘-5-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 341(5-(푸란-2-일)-2-(3-하이드록시프로필아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 342N-(4-(옥사졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 346(5-(피리딘-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 347(5-(티아졸-2-일)-2-(1H-1,2,4-티아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 348(2-(3-하이드록시프로필아미노)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 350N-(4-(피리딘-4-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 352(2-아미노-5-(피리딘-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 354(5-(푸란-2-일)-2-(1H-이미다졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 357(2-플루오로-5-(이속사졸-5-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 359(5-(옥사졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 360(2-(3-하이드록시프로필아미노)-5-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 363(2-(3-하이드록시프로필아미노)-5-(1H-파이롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 364(3-(2,3-다이하이드록시프로필)-5-(푸란-2-일)-2-메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 365(2-(피리미딘-5-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 366(5-(푸란-2-일)-2-(피라진-2-일아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 367(5-(푸란-2-일)-2-(피리딘-2-일아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 368(2-(2-(1H-이미다졸-4-일)에틸아미노)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 369(5-(푸란-2-일)-2-(3-하이드록시피롤리딘-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 370(S)-(5-(푸란-2-일)-2-(2-(하이드록시메틸)피롤리딘-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 371(5-(푸란-2-일)-2-(4-(2-하이드록시에틸)피페라진-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 372(2-(1,2-다이하이드록시에틸)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 3734-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)벤조산;화합물 3744-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)벤조산 메틸 에스테르;화합물 375(2-(옥사졸-5-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 376(2-(3-아미노-1H-1,2,4-트리아졸-1-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 377(3-(1,3-다이옥산-2-일)-4,5-다이메톡시페닐)(5-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)메탄온;화합물 378(5-(푸란-2-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3-(하이드록시메틸)-4,5-다이메톡시페닐)메탄온;화합물 379(5-(푸란-2-일)-2-(1H-1,2,3,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 380(2-(3-하이드록시프로필아미노)-5-(피리딘-2-일)페닐)(3,4,5-트라이메톡시페 닐)메탄온;화합물 381(5-(피리딘-2-일)-2-(1H-1,2,3,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 382(5-(푸란-2-일)-2-(4-하이드록시부틸아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 383(5-(푸란-2-일)-2-(피리딘-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 384(S)-(2-(3-(다이메틸아미노)피롤리딘-1-일)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 385(R)-(2-(3-(다이메틸아미노)피롤리딘-1-일)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 386(S)-N-(1-(4-(푸란-2-일)-2-(3,4,5,-트라이메톡시벤조일)페닐)피롤리딘-3-일)아세트아마이드;화합물 387(R)-N-(1-(4-(푸란-2-일)-2-(3,4,5,-트라이메톡시벤조일)페닐)피롤리딘-3- 일)아세트아마이드;화합물 388(S)-(2-(3-아미노피롤리딘-1-일)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 389(R)-(2-(3-아미노피롤리딘-1-일)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 390(5-(푸란-2-일)-2-몰폴리노페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 391(5-(티오펜-2-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 392(2-(피리딘-4-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 393(4'-메톡시-4-(티아졸-2-일)바이페닐-2-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 394(2-(2-메톡시피리딘-3-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 395(5-(티아졸-2-일)-2-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 3964-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)벤조산 메톡시메틸 에스테르;화합물 3972-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)벤즈아미도)아세트산 메틸 에스테르;화합물 399(5-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄티온;화합물 400(5-(1H-이미다졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 401(2-(1H-테트라졸-1-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 402(2-(3-아미노페녹시)-5-(티오펜-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 403(2-(3-아미노페녹시)-5-(피리딘-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 4061-(4-(푸란-2-일)-2-(1-(3,4,5-트라이메톡시페닐)바이닐)페닐)-1-1H-1,2,4-트리아졸;화합물 4084-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)벤즈아마이드;화합물 409(5-(1H-파이롤-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 410(5-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 411(2-메톡시-5-(티아졸-2-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 420(2-(4-하이드록시페닐아미노)-5-(티아졸-2-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 421(2-(3-하이드록시프로필아미노)-5-(티아졸-2-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 422(2-(벤질아미노)-5-(티아졸-2-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄 온;화합물 425(5-(푸란-2-일)-2-메톡시페닐)(펜타플루오로페닐)메탄온;화합물 426(2-아미노-5-(티아졸-2-일)피리딘-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 427N-(5-(티아졸-2-일)-3-(3,4,5-트라이메톡시벤조일)피리딘-2-일)아세트아마이드;화합물 429(2-메톡시-5-(티아졸-2-일)페닐)(펜타플루오로페닐)메탄온;화합물 434(3-((다이메틸아미노)메틸)-5-(푸란-2-일)-2-하이드록시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 437(2-플루오로-4-(푸란-2-일)페닐)(펜타플루오로페닐)메탄온;화합물 443(4-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 444(4-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(페닐)메탄온;화합물 446(4-(푸란-2-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(펜타플루오로페닐)메탄온;화합물 455(4-(피리미딘-5-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 456(2'-하이드록시-3-(1H-1,2,4-트리아졸-1-일)바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 457(2'-하이드록시-3-(플루오로)바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 458(2-플루오로-4-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 462(4-(티오펜-3-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 463(2-플루오로-4-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 464(4-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 469(2-(3-하이드록시프로필아미노)-4-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 474(4'-메톡시-4-[1,2,4]트리아졸-1-일-바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 475(4-(3,5-다이메틸-이소옥사졸-4-일)-2-[1,2,4]트리아졸-1-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 476N-(3'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)바이페닐-3-일)메탄설폰아마이드;화합물 477(3'-하이드록시-3-[1,2,4]트리아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 479(3'-에탄설포닐-3-[1,2,4]트리아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 4803'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-카복실산 메틸 에스테르;화합물 482(4'-메탄설포닐-3-[1,2,4]트리아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 483N-(3'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-일)아세트아마이드;화합물 484메탄설폰산 5-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐 에스테르;화합물 485(4-하이드록시-3,5-다이메톡시페닐)(5-티아졸-2-일-2-[1,2,4]티아졸-1-일-페닐)메탄온;화합물 486N-[4'-플루오로-3'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-일]-메탄설폰아마이드;화합물 492(2-아미노-4-티오펜-3-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 493(2-아미노-4-푸란-2-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 494N-(3'-아미노-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-일)메탄설폰아마이드;화합물 495펜타플루오로페닐-(4-티아졸-2-일-2-[1,2,4]티아졸-1-일-페닐)메탄온;화합물 497(2-아미노-4-티아졸-2-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 499(2-(4-메톡시-벤질아미노)-4-(티아졸-2-일)-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 500(3,4-다이메톡시-5-((메톡시메톡시)메틸)페닐)(4-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)메탄온;화합물 501(3-하이드록시메틸-4,5-다이메톡시페닐)(4-티아졸-2-일-2-[1,2,4]트리아졸-1-일-페닐)메탄온;화합물 502(2-(2-하이드록시에틸아미노)-4-(티아졸-2-일)페닐)(3-하이드록시메틸-4,5-다이메톡시페닐)메탄온;화합물 503(2-아미노-4-티아졸-2-일-페닐)(3-하이드록시메틸-4,5-다이메톡시페닐)메탄온;화합물 505(4-(2-아미노-티아졸-4-일)-2-플루오로-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 5063'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-카르보나이트릴;화합물 507(3',5'-다이메틸-3-[1,2,4]티아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 508(3'-나이트로-3-[1,2,4]티아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 509(3-하이드록시메틸-4,5-다이메톡시-페닐)(5-티아졸-2-일-2-[1,2,4]티아졸-1-일-페닐)메탄온;화합물 510(4-티아졸-2-일-2-[1,2,3]티아졸-1-일-페닐)(3,4,5-트라이메톡시페닐)메탄 온;화합물 511(4-피리딘-3-일-2-[1,2,4]티아졸-1-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 512(4-(4-메톡시피리딘-3-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 513(3',5'-다이플루오로-3-[1,2,4]트리아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 514(3-브로모-4,5-다이메톡시페닐)(2-플루오로-4-(티아졸-2-일)페닐)메탄온;화합물 515(3-브로모-4,5-다이메톡시페닐)(4-(티아졸-2-일)-2-(1,2,4-트리아졸-1-일)페닐)메탄온;화합물 516(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 517(4-(2-메틸티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡 시페닐)메탄온;화합물 518(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(펜타플루오로페닐)메탄온;화합물 519(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(페닐)메탄온;화합물 525(3’-아미노-3-(1H-1,2,4-트리아졸-1-일)바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 531N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)-1H-이미다졸-2-일)아세트아마이드;화합물 534(4-(티아졸-5-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 538(4-(다이플루오로메톡시)-3,5-다이메톡시페닐)(4-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)메탄온;화합물 547(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(4-(다이플루오 로메톡시)-3,5-다이메톡시페닐)메탄온;화합물 550(5’-(1H-1,2,4-트리아졸-1-일)-4’-(3,4,5-트라이메톡시벤조일)바이페닐-3-설폰아마이드;화합물 554((4-(4-하이드록시메틸)티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 560N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)티아졸-2-일)아세트아마이드;화합물 561메틸 4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)티아졸-2-일 카바메이트;화합물 562(4-(티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 563(4-(2-(2-하이드록시프로판-2-일)티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 564(4-(2-(하이드록시메틸)티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 568(3-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 570(3-(2-아미노티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 571(4-(2-아미노티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 581(3-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 583(2-메톡시-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 587(3-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 588(2-메톡시-5-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 590(2-메톡시-5-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 591(3-(1H-피롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 594(2-메톡시-5-(티오펜-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 595(2-메톡시-5-(메틸티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 596(5-(2-메틸티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 597(2-아미노-5-(1H-피롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 598(2-메톡시-5-(1H-피라졸-5-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 599(4-(1H-피롤-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 601(2-하이드록시-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온; 및화합물 602(4-(옥사졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온.
- 제 1 항에 있어서, 하기 화합물로부터 선택된 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물:화합물 200(2-메톡시-5-(피리딘-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 203(5-(푸란-2-일)-2-메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 206(5-(푸란-2-일)-2,3-다이메톡시페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 213(4,4'-다이메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 249(5-(푸란-2-일)-2-메톡시페닐)(3-(하이드록시메틸)-4,5-다이메톡시페닐)메탄온;화합물 264(5-(푸란-2-일)-2-메톡시페닐)(4-메톡시-3,5-다이메틸페닐)메탄온;화합물 265(5-(푸란-2-일)-2-메톡시페닐)(4-(메톡시메톡시)-3,5-다이메틸페닐)메탄온;화합물 269(3-알릴-4-하이드록시-5-메톡시페닐)(5-(푸란-2-일)-2-메톡시페닐)메탄온;화합물 583(2-메톡시-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 588(2-메톡시-5-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 590(2-메톡시-5-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 594(2-메톡시-5-(티오펜-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 595(2-메톡시-5-(메틸티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온; 및화합물 598(2-메톡시-5-(1H-피라졸-5-일)페닐)(3,4,5-트라이메톡시페닐)메탄온.
- 제 1 항에 있어서, 하기 화합물로부터 선택된 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물:화합물 224(5-(푸란-2-일)-2-나이트로페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 225(2-아미노-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 226(4-아미노-4'-메톡시바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 231N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 235N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 2372-아미노-N-(4-(푸란-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 238(2-(알릴아미노)-5-(푸란-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 272(2-아미노-4-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 277N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 278(2-아미노-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 279N-(4-(티오펜-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 282(5-(푸란-2-일)-2-(메틸아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 283(2-아미노-5-(티오펜-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 286(2-아미노-5-(티아졸-2-일)페닐)(3-(하이드록시메틸)-4,5-다이메톡시페닐)메탄온;화합물 289(2-아미노-5-(옥사졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 293(2-아미노-5-(피리딘-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 294N-(4-(2-아미노티아졸-5-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 296N-(4-(옥사졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 297(2-아미노-5-(2-아미노티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 298(2-아미노-5-(2-메틸티아졸-4-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 300N-(4-(티오펜-3-일)-2-(3,4,5-트라이메톡시벤조일)페닐)아세트아마이드;화합물 301(2-아미노-5-(티오펜-3-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 308N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 316N-(4-(티아졸-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)포름아마이드;화합물 323(5-(푸란-2-일)-2-(2-하이드록시에틸아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 335N-(4-(피리딘-2-일)-2-(3,4,5-트라이메톡시벤조일)페닐)메탄설폰아마이드;화합물 337(4,5'-다이아미노페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 341(5-(푸란-2-일)-2-(3-하이드록시프로필아미노)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 348(2-(3-하이드록시프로필아미노)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 354(5-(푸란-2-일)-2-(1H-이미다졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 363(2-(3-하이드록시프로필아미노)-5-(1H-파이롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 379(5-(푸란-2-일)-2-(1H-1,2,3,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 380(2-(3-하이드록시프로필아미노)-5-(피리딘-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 401(2-(1H-테트라졸-1-일)-5-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 469(2-(3-하이드록시프로필아미노)-4-(티아졸-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 494N-(3'-아미노-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-일)메탄설폰아마이드; 및화합물 597(2-아미노-5-(1H-피롤-2-일)페닐)(3,4,5-트라이메톡시페닐)메탄온.
- 제 1 항에 있어서, 하기 화합물로부터 선택된 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물:화합물 322(5-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 346(5-(피리딘-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 347(5-(티아졸-2-일)-2-(1H-1,2,4-티아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 359(5-(옥사졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 391(5-(티오펜-2-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 400(5-(1H-이미다졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 409(5-(1H-파이롤-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 443(4-(푸란-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 446(4-(푸란-2-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(펜타플루오로페닐)메탄온;화합물 455(4-(피리미딘-5-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 462(4-(티오펜-3-일)-2-(1H-1,2,4,-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 464(4-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 474(4'-메톡시-4-[1,2,4]트리아졸-1-일-바이페닐-3-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 475(4-(3,5-다이메틸-이소옥사졸-4-일)-2-[1,2,4]트리아졸-1-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 476N-(3'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)바이페닐-3-일)메탄설폰아마이드;화합물 479(3'-에탄설포닐-3-[1,2,4]트리아졸-1-일-바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 5063'-[1,2,4]트리아졸-1-일-4'-(3,4,5-트라이메톡시벤조일)-바이페닐-3-카르보나이트릴;화합물 511(4-피리딘-3-일-2-[1,2,4]티아졸-1-일-페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 519(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(페닐)메탄온;화합물 525(3’-아미노-3-(1H-1,2,4-트리아졸-1-일)바이페닐-4-일)(3,4,5-트라이메톡시페닐)메탄온;화합물 531N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)-1H-이미다졸-2-일)아세트아마이드;화합물 534(4-(티아졸-5-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 538(4-(다이플루오로메톡시)-3,5-다이메톡시페닐)(4-(티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)메탄온;화합물 547(4-(2-아미노티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(4-(다이플루오로메톡시)-3,5-다이메톡시페닐)메탄온;화합물 550(5’-(1H-1,2,4-트리아졸-1-일)-4’-(3,4,5-트라이메톡시벤조일)바이페닐-3-설폰아마이드;화합물 554((4-(4-하이드록시메틸)티아졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4, 5-트라이메톡시페닐)메탄온;화합물 560N-(4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)티아졸-2-일)아세트아마이드;화합물 561메틸 4-(3-(1H-1,2,4-트리아졸-1-일)-4-(3,4,5-트라이메톡시벤조일)페닐)티아졸-2-일 카바메이트;화합물 562(4-(티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 563(4-(2-(2-하이드록시프로판-2-일)티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 564(4-(2-(하이드록시메틸)티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 596(5-(2-메틸티아졸-4-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온;화합물 599(4-(1H-피롤-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온; 및화합물 602(4-(옥사졸-2-일)-2-(1H-1,2,4-트리아졸-1-일)페닐)(3,4,5-트라이메톡시페닐)메탄온.
- 제 1 항의 화합물, 이의 이성질체, 약제학적으로 허용가능한 이의 염, 이의 수화물 또는 이의 용매화물을 유효성분으로 하고, 약제학적으로 허용되는 부형제 또는 담체를 포함하는, 미세소관 형성 저해 작용이 있는 약제학적 조성물.
- 제 18 항에 있어서, 악성종양, 바이러스 및 세균감염, 혈관재발협착증, 염증성 질환, 자가면역질환 또는 건선 치료용 약제학적 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060094019 | 2006-09-27 | ||
KR20060094019 | 2006-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080028763A true KR20080028763A (ko) | 2008-04-01 |
KR100932093B1 KR100932093B1 (ko) | 2009-12-16 |
Family
ID=39230347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070083856A KR100932093B1 (ko) | 2006-09-27 | 2007-08-21 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8053439B2 (ko) |
EP (1) | EP2066632B1 (ko) |
KR (1) | KR100932093B1 (ko) |
ES (1) | ES2437079T3 (ko) |
WO (1) | WO2008038955A1 (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263585B2 (en) | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
CA2719243C (en) * | 2008-03-26 | 2013-06-25 | Chong Kun Dang Pharmaceutical Corp. | Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
ES2927660T3 (es) | 2008-06-16 | 2022-11-10 | Univ Tennessee Res Found | Compuestos para el tratamiento del cáncer |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
KR20120130777A (ko) * | 2010-03-01 | 2012-12-03 | 유니버시티 오브 테네시 리서치 파운데이션 | 암 치료용 화합물 |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
GB2486631A (en) * | 2010-12-01 | 2012-06-27 | Univ Sheffield | Phenol/quinone boronic acids/esters and method of preparation thereof |
JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
CN103524320A (zh) * | 2013-09-11 | 2014-01-22 | 西安交通大学 | 一种取代二苯甲酮及其制备的方法 |
US9980953B2 (en) | 2016-09-26 | 2018-05-29 | Chong Kun Dang Pharmaceutical Corp. | Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor |
CN106632000B (zh) * | 2016-12-19 | 2019-04-26 | 湖北工业大学 | 二芳基甲酮化合物在制备抗肿瘤药物中的应用 |
CN108283641A (zh) * | 2017-12-27 | 2018-07-17 | 湖北工业大学 | 二芳基甲酮系列化合物用于制备抗肿瘤药物 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
KR102264110B1 (ko) * | 2018-05-30 | 2021-06-11 | 이화여자대학교 산학협력단 | 신규 바이페닐 유도체 화합물 및 이의 용도 |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
CN115477626A (zh) * | 2021-06-16 | 2022-12-16 | 上海璃道医药科技有限公司 | N-取代苯基磺酰胺类化合物及其用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE757702A (fr) | 1969-10-20 | 1971-04-19 | Sandoz Sa | Derives de la pyrido (2,3-d) pyrimidine, leur preparation et medicaments les contenant. |
IL38234A0 (en) | 1970-12-23 | 1972-01-27 | Sparamedica Ag | Benzodiazepine derivatives,their manufacture and pharmaceutical compositions containing them |
US3900501A (en) | 1970-12-23 | 1975-08-19 | Hoffmann La Roche | Benzophenone intermediates for 7-lower alkanoyl benzodiazepines |
JPS57167979A (en) * | 1981-04-08 | 1982-10-16 | Kanzaki Paper Mfg Co Ltd | Phthalide derivative, its preparation, recording material using it |
US4579679A (en) * | 1981-05-18 | 1986-04-01 | Chevron Research Company | Electroactive polymers |
JPS58150566A (ja) * | 1982-03-03 | 1983-09-07 | Yoshitomi Pharmaceut Ind Ltd | 新規イミダゾ−ル誘導体 |
AU710173B2 (en) | 1996-07-19 | 1999-09-16 | Tularik Inc. | Pentafluorobenzenesulfonamides and analogs |
JP2002500184A (ja) | 1998-01-09 | 2002-01-08 | アリゾナ ボード オブ リーゼンツ | フェンスタチンとそのプロドラッグの合成 |
WO2000050398A2 (en) * | 1999-02-24 | 2000-08-31 | F. Hoffmann-La Roche Ag | Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists |
WO2001081288A1 (en) | 2000-04-27 | 2001-11-01 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Hydroxyphenstatin and the prodrugs thereof |
US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
MXPA04012959A (es) | 2002-06-29 | 2005-05-16 | Zentaris Gmbh | Arilcarbonilpiperacinas y heteroarilcarbonilpiperacinas y su uso para tratamiento de enfermedades de tumor benigno y maligno. |
DE60316688T2 (de) | 2002-08-02 | 2008-07-17 | Nereus Pharmaceuticals, Inc., San Diego | Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon |
CN101053558A (zh) * | 2003-03-05 | 2007-10-17 | 细胞基因公司 | 二苯基乙烯化合物及其用途 |
CN1826310B (zh) | 2003-07-24 | 2010-07-21 | 利奥制药有限公司 | 新的氨基二苯酮化合物 |
WO2005100301A1 (en) | 2004-03-31 | 2005-10-27 | Eli Lilly And Company | 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors |
PL1828148T3 (pl) | 2004-12-13 | 2010-08-31 | Leo Pharma As | Triazol podstawiony związkami aminobenzofenonu |
-
2007
- 2007-08-21 KR KR1020070083856A patent/KR100932093B1/ko active IP Right Grant
- 2007-09-21 WO PCT/KR2007/004625 patent/WO2008038955A1/en active Application Filing
- 2007-09-21 EP EP07808403.5A patent/EP2066632B1/en active Active
- 2007-09-21 US US12/441,601 patent/US8053439B2/en active Active
- 2007-09-21 ES ES07808403.5T patent/ES2437079T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
ES2437079T3 (es) | 2014-01-08 |
KR100932093B1 (ko) | 2009-12-16 |
US20090275575A1 (en) | 2009-11-05 |
US8053439B2 (en) | 2011-11-08 |
EP2066632A4 (en) | 2011-04-27 |
EP2066632B1 (en) | 2013-09-04 |
EP2066632A1 (en) | 2009-06-10 |
WO2008038955A1 (en) | 2008-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100932093B1 (ko) | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 | |
KR101507173B1 (ko) | 페록시좀 증식제 활성화 수용체 δ 의 활성화제 | |
ES2218548T3 (es) | Derivados de fenilo trisustituidos, utiles como inhibidores de la pde iv. | |
EP0733033B1 (en) | Pharmaceutically active substituted aromatic compounds | |
AU2003237787B2 (en) | Substituted phenylacetic acids | |
KR100706736B1 (ko) | 페닐헤테로알킬아민 유도체의 신규 용도 | |
US5527827A (en) | Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis | |
JP2003522766A5 (ko) | ||
US4857539A (en) | Heterocyclic substituted-phenoxyalkylisoxazoles as antiviral useful agents | |
JP2005533858A (ja) | 化合物 | |
AU756221B2 (en) | 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them | |
CA2621038A1 (en) | Triarylcarboxylic acid derivative | |
MXPA06013591A (es) | Compuestos y composiciones como moduladores del receptor activado por poliferador de peroxisoma (ppar). | |
KR20070074250A (ko) | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 | |
JPH0768242B2 (ja) | 複素環式置換フエノキシアルキル−イソオキサゾ−ルおよび−フラン、それらの製法および抗ウイルス剤としての用法 | |
US20150315143A1 (en) | N-Heterocyclic Carbene-Catalyzed Synthesis of 2-Aryl Indoles | |
HU211296A9 (en) | Lignan analogues, methods of preparation thereof and anti-hyperlipemic agents | |
KR19990029982A (ko) | 신규한 피페라진 및 피페리딘 화합물 | |
JP4459268B2 (ja) | インデン誘導体及びその製造方法 | |
US5270319A (en) | 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents | |
JP3781464B2 (ja) | オキサゾール中間体を介するアリールピロール殺虫剤の製造法 | |
CZ220296A3 (en) | Process for preparing derivatives of arylacetic acid esters and intermediates employed in the process | |
Buscemi et al. | A generalized synthesis of 3-amino-5-aryl-, 3-amino-5-polyfluorophenyl-, and 3-amino-5-alkyl-1, 2, 4-oxadiazoles through ring-degenerate rearrangements | |
US11584742B2 (en) | Substituted aminothiazoles as inhibitors of nucleases | |
US4072689A (en) | Monoamino 2,4,5-trisubstituted oxazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121106 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131111 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151020 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170913 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181016 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190925 Year of fee payment: 11 |